Global Veterinary Vaccines Market 2017-2021
出 版 商：Technavio
出版日期：2017/05/03
頁 數：70頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
ABSTRACT
About Veterinary Vaccines
Vaccines play a crucial role in protecting animals from a large spectrum of diseases caused due to virus, bacteria, protozoa, and other multicellular pathogens. The global veterinary vaccines market is expected to benefit from the growing concern over food safety. The dependency on livestock products like meat, milk, and other products is increasing, and the mortality rate associated with infection transmission from animals to humans through these products is alarming. These factors are driving the vendors to invest in R&D to improve and expand their product portfolios, thereby driving the market growth.
Technavio’s analysts forecast the global veterinary vaccines market to grow at a CAGR of 4.81% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global veterinary vaccines market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Veterinary Vaccines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Elanco
‧ Merck
‧ Merial
‧ Zoetis
Other prominent vendors
‧ Advaxis
‧ AmpliPhi Biosciences
‧ Aratana Therapeutics
‧ ARKO Labs
‧ Bayer
‧ CanFel Therapeutics
‧ Ceva Animal Health
‧ Colorado Serum Company
‧ Epitopix
‧ Genus
‧ Hygieia Biological Laboratories
‧ ImmuCell
‧ Nexvet
‧ Nuovo Biologics
‧ UBI
‧ Valneva
‧ Vetoquinol
‧ Virbac
Market driver
‧ Dependency on livestock products.
‧ For a full, detailed list, view our report
Market challenge
‧ Manufacturing and storage issues.
‧ For a full, detailed list, view our report
Market trend
‧ Robust R&D and improved product portfolio.
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
About Veterinary Vaccines
Vaccines play a crucial role in protecting animals from a large spectrum of diseases caused due to virus, bacteria, protozoa, and other multicellular pathogens. The global veterinary vaccines market is expected to benefit from the growing concern over food safety. The dependency on livestock products like meat, milk, and other products is increasing, and the mortality rate associated with infection transmission from animals to humans through these products is alarming. These factors are driving the vendors to invest in R&D to improve and expand their product portfolios, thereby driving the market growth.
Technavio’s analysts forecast the global veterinary vaccines market to grow at a CAGR of 4.81% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global veterinary vaccines market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Veterinary Vaccines Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Elanco
‧ Merck
‧ Merial
‧ Zoetis
Other prominent vendors
‧ Advaxis
‧ AmpliPhi Biosciences
‧ Aratana Therapeutics
‧ ARKO Labs
‧ Bayer
‧ CanFel Therapeutics
‧ Ceva Animal Health
‧ Colorado Serum Company
‧ Epitopix
‧ Genus
‧ Hygieia Biological Laboratories
‧ ImmuCell
‧ Nexvet
‧ Nuovo Biologics
‧ UBI
‧ Valneva
‧ Vetoquinol
‧ Virbac
Market driver
‧ Dependency on livestock products.
‧ For a full, detailed list, view our report
Market challenge
‧ Manufacturing and storage issues.
‧ For a full, detailed list, view our report
Market trend
‧ Robust R&D and improved product portfolio.
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
‧ What are the market opportunities and threats faced by the key vendors?
‧ What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
PART 05: An overview of major animal diseases
PART 06: Market landscape
‧ Market overview
‧ Five forces analysis
PART 07: Market segmentation by technology
‧ Live attenuated vaccines
‧ Inactivated/Killed vaccines
‧ Toxoid vaccines
‧ DNA vaccines
‧ Recombinant vector vaccines
PART 08: Geographical segmentation
‧ Veterinary vaccines market in Americas
‧ Veterinary vaccines market in EMEA
‧ Veterinary vaccines market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 11: Market trends
PART 12: Vendor landscape
‧ Competitive scenario
PART 13: Key vendor analysis
‧ Elanco
‧ Merck
‧ Merial
‧ Zoetis
‧ Other prominent vendors
PART 14: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Overview of major animal diseases
Exhibit 02: Global veterinary vaccines market snapshot
Exhibit 03: Global veterinary vaccines market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global veterinary vaccines market
Exhibit 05: Five forces analysis
Exhibit 06: Market segmentation by technology 2016
Exhibit 07: Veterinary live attenuated vaccines: Vendors and indications
Exhibit 08: Global veterinary live attenuated vaccines market 2016-2021 ($ millions)
Exhibit 09: Veterinary inactivated vaccines: Vendors and indications
Exhibit 10: Global veterinary inactivated vaccines market 2016-2021 ($ millions)
Exhibit 11: Examples: Veterinary toxoid vaccines with their indications and vendors
Exhibit 12: Global veterinary toxoid vaccines market 2016-2021 ($ millions)
Exhibit 13: Veterinary DNA vaccines
Exhibit 14: Global veterinary DNA vaccines market 2016-2021 ($ millions)
Exhibit 15: Veterinary recombinant vector vaccines
Exhibit 16: Global veterinary recombinant vector vaccines market 2016-2021 ($ millions)
Exhibit 17: Global veterinary vaccines market by geography 2016 and 2021
Exhibit 18: Global veterinary vaccines market revenue by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: Veterinary vaccines market in Americas 2016-2021 ($ millions)
Exhibit 21: Market scenario in EMEA
Exhibit 22: Veterinary vaccines market in EMEA 2016-2021 ($ millions)
Exhibit 23: Market scenario in APAC
Exhibit 24: Veterinary vaccines market in APAC 2016-2021 ($ millions)
Exhibit 25: Major requirements for CVB product approval
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Key drivers and challenges for impact analysis
Exhibit 28: Recent strategic alliances in animal healthcare
Exhibit 29: Competitive structure analysis of global veterinary vaccines market 2016
Exhibit 30: Competitive factors of global veterinary vaccines market
Exhibit 31: Market penetration of lifestyle drug manufacturers worldwide 2016
Exhibit 32: Strategic success factors of companies in global veterinary vaccine market
Exhibit 33: Key news in veterinary vaccines market
Exhibit 34: Elanco: Key highlights
Exhibit 35: Elanco: Strength assessment
Exhibit 36: Elanco: Strategy assessment
Exhibit 37: Elanco: Opportunity assessment
Exhibit 38: Merck: Key highlights
Exhibit 39: Merck: Strength assessment
Exhibit 40: Merck: Strategy assessment
Exhibit 41: Merck: Opportunity assessment
Exhibit 42: Merial: Key highlights
Exhibit 43: Merial: Strength assessment
Exhibit 44: Merial: Strategy assessment
Exhibit 45: Merial: Opportunity assessment
Exhibit 46: Zoetis: Key highlights
Exhibit 47: Zoetis: Strength assessment
Exhibit 48: Zoetis: Strategy assessment
Exhibit 49: Allergan: Opportunity assessment
Exhibit 50: Other prominent vendors
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
‧ Key market highlights
PART 05: An overview of major animal diseases
PART 06: Market landscape
‧ Market overview
‧ Five forces analysis
PART 07: Market segmentation by technology
‧ Live attenuated vaccines
‧ Inactivated/Killed vaccines
‧ Toxoid vaccines
‧ DNA vaccines
‧ Recombinant vector vaccines
PART 08: Geographical segmentation
‧ Veterinary vaccines market in Americas
‧ Veterinary vaccines market in EMEA
‧ Veterinary vaccines market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 11: Market trends
PART 12: Vendor landscape
‧ Competitive scenario
PART 13: Key vendor analysis
‧ Elanco
‧ Merck
‧ Merial
‧ Zoetis
‧ Other prominent vendors
PART 14: Appendix
‧ List of abbreviations
List of Exhibits
Exhibit 01: Overview of major animal diseases
Exhibit 02: Global veterinary vaccines market snapshot
Exhibit 03: Global veterinary vaccines market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global veterinary vaccines market
Exhibit 05: Five forces analysis
Exhibit 06: Market segmentation by technology 2016
Exhibit 07: Veterinary live attenuated vaccines: Vendors and indications
Exhibit 08: Global veterinary live attenuated vaccines market 2016-2021 ($ millions)
Exhibit 09: Veterinary inactivated vaccines: Vendors and indications
Exhibit 10: Global veterinary inactivated vaccines market 2016-2021 ($ millions)
Exhibit 11: Examples: Veterinary toxoid vaccines with their indications and vendors
Exhibit 12: Global veterinary toxoid vaccines market 2016-2021 ($ millions)
Exhibit 13: Veterinary DNA vaccines
Exhibit 14: Global veterinary DNA vaccines market 2016-2021 ($ millions)
Exhibit 15: Veterinary recombinant vector vaccines
Exhibit 16: Global veterinary recombinant vector vaccines market 2016-2021 ($ millions)
Exhibit 17: Global veterinary vaccines market by geography 2016 and 2021
Exhibit 18: Global veterinary vaccines market revenue by geography 2016-2021 ($ millions)
Exhibit 19: Market scenario in Americas
Exhibit 20: Veterinary vaccines market in Americas 2016-2021 ($ millions)
Exhibit 21: Market scenario in EMEA
Exhibit 22: Veterinary vaccines market in EMEA 2016-2021 ($ millions)
Exhibit 23: Market scenario in APAC
Exhibit 24: Veterinary vaccines market in APAC 2016-2021 ($ millions)
Exhibit 25: Major requirements for CVB product approval
Exhibit 26: Impact of drivers and challenges
Exhibit 27: Key drivers and challenges for impact analysis
Exhibit 28: Recent strategic alliances in animal healthcare
Exhibit 29: Competitive structure analysis of global veterinary vaccines market 2016
Exhibit 30: Competitive factors of global veterinary vaccines market
Exhibit 31: Market penetration of lifestyle drug manufacturers worldwide 2016
Exhibit 32: Strategic success factors of companies in global veterinary vaccine market
Exhibit 33: Key news in veterinary vaccines market
Exhibit 34: Elanco: Key highlights
Exhibit 35: Elanco: Strength assessment
Exhibit 36: Elanco: Strategy assessment
Exhibit 37: Elanco: Opportunity assessment
Exhibit 38: Merck: Key highlights
Exhibit 39: Merck: Strength assessment
Exhibit 40: Merck: Strategy assessment
Exhibit 41: Merck: Opportunity assessment
Exhibit 42: Merial: Key highlights
Exhibit 43: Merial: Strength assessment
Exhibit 44: Merial: Strategy assessment
Exhibit 45: Merial: Opportunity assessment
Exhibit 46: Zoetis: Key highlights
Exhibit 47: Zoetis: Strength assessment
Exhibit 48: Zoetis: Strategy assessment
Exhibit 49: Allergan: Opportunity assessment
Exhibit 50: Other prominent vendors
